^
    Back
    Association details:
    Biomarker:HAT1 overexpression
    Cancer:Leiomyosarcoma
    Drug:Votrient (pazopanib) (Multi-tyrosine kinase inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: D – Preclinical
    New
    Source:
    J Mol Med (Berl)
    Title:

    Synergistic effects of pazopanib and hyperthermia against uterine leiomyosarcoma growth mediated by downregulation of histone acetyltransferase 1

    Excerpt:
    ...with high HAT1 expression levels being associated with poor clinical outcomes (p = 0.007)….Pazopanib and hyperthermia inhibit the growth of leiomyosarcoma.
    DOI:
    10.1007/s00109-020-01888-w